Hua MedicineHUMDF 46 Pretax Margin % is -28.16% as of Dec. 2025. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Hua Medicine ranks better than 99.37% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Hua Medicine's Pre-Tax Income for the
six
months ended in Dec. 2025 was $-11.02 Mil. Hua Medicine's Revenue for the
six
months ended in Dec. 2025 was $39.12 Mil. Therefore, Hua Medicine's pretax margin for the quarter that ended in Dec. 2025 was -28.16%.
The historical rank and industry rank for Hua Medicine's Pretax Margin % or its related term are showing as below:
HUMDF'
s Pretax Margin % Range Over the Past 10 Years
Min: -1156.36 Med: -186.74 Max: 224.44
Current: 222.95
HUMDF's Pretax Margin % is ranked better than 99.37% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs HUMDF: 222.95
Hua Medicine (OTCPK:HUMDF) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Hua Medicine Pretax Margin % Related Terms
Hua Medicine Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Hua Medicine's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Hua Medicine's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a Pretax Margin % of -28.16% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Hua Medicine and its competitors. According to the industry distribution chart, Hua Medicine ranks #6 out of 952 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Hua Medicine's Pretax Margin % too high?
Hua Medicine's current Pretax Margin % is -28.16%. Based on the distribution chart, Hua Medicine ranks #6 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #6 out of 952 companies for Pretax Margin %. This places Hua Medicine in the top 1% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current Pretax Margin % is -28.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.46, compared to a current price of $0.34 — trading 76.7% below its estimated fair value. The current Pretax Margin % is -28.16%. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current Pretax Margin % is -28.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.34 is trading 76.7% below its estimated GF Value™ of $1.46.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
Pretax Margin %: -28.16%
GF Value™: $1.46 vs. price of $0.34 (76.7% below fair value)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score
Get the complete analysis for HUMDF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
